Rankings
▼
Calendar
AKBA Q4 2024 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AKBA
Akebia Therapeutics, Inc.
$365M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$46M
-17.3% YoY
Gross Profit
$26M
56.2% margin
Operating Income
-$14M
-30.8% margin
Net Income
-$23M
-49.0% margin
EPS (Diluted)
$-0.10
QoQ Revenue Growth
+24.2%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$221M
Total Liabilities
$270M
Stockholders' Equity
-$49M
Cash & Equivalents
$52M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$46M
$56M
-17.3%
Gross Profit
$26M
$38M
-30.4%
Operating Income
-$14M
$1M
-1141.3%
Net Income
-$23M
$614,000
-3814.0%
Revenue Segments
Product
$86M
95%
License Collaboration And Other Revenue
$5M
5%
← FY 2024
All Quarters
Q1 2025 →